Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma
(1, 2)
,
(1, 3)
,
(4, 3)
,
(4, 3)
,
(1, 3, 5, 6)
,
(1, 3)
,
(7)
,
(1, 3)
,
(1, 3, 8)
,
(8)
,
(8)
,
(1, 3)
,
(4)
,
(4)
,
(1, 3)
,
(1, 3)
,
(1, 3)
,
(1, 3)
,
(4)
,
(1, 3)
,
(9, 10)
,
(11)
,
(1, 3)
,
(12)
,
(12, 13, 14)
,
(15)
,
(1, 3)
,
(5, 6, 3)
,
(5, 6, 3, 16)
,
(17, 18, 19)
,
(1, 3)
,
(4, 3)
,
(7)
,
(1, 3)
,
(1, 5, 6, 3)
,
(3, 4)
,
(1, 3, 8)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
Nicolas Jacquelot
- Function : Author
- PersonId : 777539
- ORCID : 0000-0003-0282-1892
- IdRef : 194083357
Cyril Seillet
- Function : Author
- PersonId : 760085
- ORCID : 0000-0002-0941-8679
Angela Pizzolla
- Function : Author
- PersonId : 822441
- ORCID : 0000-0003-2024-4144
Soroor Hediyeh-Zadeh
- Function : Author
- PersonId : 798301
- ORCID : 0000-0001-7513-6779
Cynthia Louis
- Function : Author
- PersonId : 803159
- ORCID : 0000-0001-8382-6358
Jaring Schreuder
- Function : Author
- PersonId : 822442
- ORCID : 0000-0002-7579-0006
Kylie Luong
- Function : Author
- PersonId : 794584
- ORCID : 0000-0002-1459-2604
Shengbo Zhang
- Function : Author
- PersonId : 822443
- ORCID : 0000-0003-3870-0590
Stephen Nutt
- Function : Author
- PersonId : 798692
- ORCID : 0000-0002-0020-6637
Joanna Groom
- Function : Author
- PersonId : 798693
- ORCID : 0000-0001-5251-7835
Philip Hansbro
- Function : Author
- PersonId : 822444
- ORCID : 0000-0002-4741-3035
Andrew Mckenzie
- Function : Author
- PersonId : 804107
- ORCID : 0000-0001-9757-2512
Daniel Gray
- Function : Author
- PersonId : 804249
- ORCID : 0000-0002-8457-8242
Eric Vivier
- Function : Author
- PersonId : 17342
- IdHAL : eric-vivier
- ORCID : 0000-0001-7022-8287
- IdRef : 076121712
Ian Wicks
- Function : Author
- PersonId : 803161
- ORCID : 0000-0001-7050-6822
Melissa Davis
- Function : Author
- PersonId : 803160
- ORCID : 0000-0003-4864-7033
Paul Neeson
- Function : Author
- PersonId : 822445
- ORCID : 0000-0002-2729-5887
Gabrielle Belz
- Function : Author
- PersonId : 798691
- ORCID : 0000-0002-9660-9587
Abstract
Group 2 innate lymphoid cells (ILC2s) are essential to maintain tissue homeostasis. In cancer, ILC2s can harbor both pro-tumorigenic and anti-tumorigenic functions, but we know little about their underlying mechanisms or whether they could be clinically relevant or targeted to improve patient outcomes. Here, we found that high ILC2 infiltration in human melanoma was associated with a good clinical prognosis. ILC2s are critical producers of the cytokine granulocyte-macrophage colony-stimulating factor, which coordinates the recruitment and activation of eosinophils to enhance antitumor responses. Tumor-infiltrating ILC2s expressed programmed cell death protein-1, which limited their intratumoral accumulation, proliferation and antitumor effector functions. This inhibition could be overcome in vivo by combining interleukin-33-driven ILC2 activation with programmed cell death protein-1 blockade to significantly increase antitumor responses. Together, our results identified ILC2s as a critical immune cell type involved in melanoma immunity and revealed a potential synergistic approach to harness ILC2 function for antitumor immunotherapies.